Clinical Trial

Impact of Soluble Arabinoxylan and Rice Bran Fiber on the Gut Microbiome in Healthy Adults

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 29, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The importance of the gut microbiota for general health has been recently elucidated, but little is known about the impact of different types of nutrients on the gut microbiota. The soluble fiber in cereal by-products, arabinoxylan (AX), is known to be beneficial for generally promoting gut health. However, it is unclear whether consuming rice bran (RB), the source of AX, is equally helpful or better than consuming the extracted form of AX. This study aims to reveal the potential benefit of insoluble cereal bran fiber ingredients by comparing the effect of soluble arabinoxylan fiber alone and the mostly insoluble rice bran fiber, containing arabinoxylan, on intestinal health and gut microbiota. A placebo (maltodextrin) will be used as a control, with no significant changes expected in this group for the evaluated outcomes. Participants will: * Consume two different fiber supplements (soluble arabinoxylan or stabilized rice bran) as well as a placebo (maltodextrin) for 3 weeks each, separated by a 2-week washout period. * Provide blood and stool samples at six different time points. * Complete a food and gastrointestinal symptom diary during the intervention periods.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-06.
Trial Details
NCT Number NCT06873204
Lead Sponsor Purdue University
Collaborators: Rural Development Administration (RDA) of the Republic of Korea
Conditions Healthy
Enrollment 25 participants
Start Date 2025-07
Primary Completion 2025-10 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-06-29